- Home
- SLXN vs CYCC Comparison
SLXN vs CYCC Comparison
Compare SLXN & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- CYCC
- Stock Information
- Founded
- SLXN 2008
- CYCC 1992
- Country
- SLXN Israel
- CYCC United States
- Employees
- SLXN N/A
- CYCC N/A
- Industry
- SLXN
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- SLXN
- CYCC Health Care
- Exchange
- SLXN NYSE
- CYCC Nasdaq
- Market Cap
- SLXN 4.3M
- CYCC 3.6M
- IPO Year
- SLXN N/A
- CYCC N/A
- Fundamental
- Price
- SLXN $0.99
- CYCC $0.25
- Analyst Decision
- SLXN Strong Buy
- CYCC Strong Buy
- Analyst Count
- SLXN 1
- CYCC 1
- Target Price
- SLXN $5.00
- CYCC $11.00
- AVG Volume (30 Days)
- SLXN 952.7K
- CYCC 160.2K
- Earning Date
- SLXN 05-21-2025
- CYCC 05-13-2025
- Dividend Yield
- SLXN N/A
- CYCC N/A
- EPS Growth
- SLXN N/A
- CYCC N/A
- EPS
- SLXN N/A
- CYCC N/A
- Revenue
- SLXN N/A
- CYCC $74,000.00
- Revenue This Year
- SLXN N/A
- CYCC N/A
- Revenue Next Year
- SLXN N/A
- CYCC $88.68
- P/E Ratio
- SLXN N/A
- CYCC N/A
- Revenue Growth
- SLXN N/A
- CYCC N/A
- 52 Week Low
- SLXN $0.21
- CYCC $0.22
- 52 Week High
- SLXN $13.56
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- CYCC 29.30
- Support Level
- SLXN N/A
- CYCC $0.29
- Resistance Level
- SLXN N/A
- CYCC $0.32
- Average True Range (ATR)
- SLXN 0.00
- CYCC 0.02
- MACD
- SLXN 0.00
- CYCC -0.00
- Stochastic Oscillator
- SLXN 0.00
- CYCC 19.92
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.